Tag: FR0013018124

Nicox SASociété anonyme with a registered capital of € 37,103,985 Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On March 2, 2021, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE S…

FOR INFORMATIONNicox Provides Video Update on Latest Developments  March 2, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided a brief video update…

Press ReleaseNicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma  February 15, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology co…

Nicox SASociété anonyme with a registered capital of € 37,030,335 Head Office:DRAKKAR D 2405 route des Dolines 06560 Valbonne Sophia-Antipolis R.C.S. GRASSE 403.942.642 On February 1, 2021, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article L.233-8 II of the Code de Commerce and Articles… Continue reading Number of voting rights as of January 31, 2021

Press Release Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021   January 29, 2021 – release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its bond financing agreement with Kreos Capital, introducing an additional one-year period… Continue reading Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021

Press Release Nicox Analyst Coverage Initiated by Edison Investment Research   January 22, 2021 – release at 7:30 am CET Sophia Antipolis, France                                                                     Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Edison, an investment research and advisory company with a world-renowned equity research platform and deep international healthcare expertise,… Continue reading Nicox Analyst Coverage Initiated by Edison Investment Research

Press Release Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights   Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE™ in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S.… Continue reading Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights

Press Release Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights   Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE™ in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S.… Continue reading Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights

Press Release Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights   Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE™ in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S.… Continue reading Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights

Press Release Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights   Initiated two large clinical trials: Denali, the second Phase 3 of NCX 470 in glaucoma, and Mississippi, a Phase 2b of NCX 4251 in blepharitis Phase 3 clinical trial of ZERVIATE™ in allergic conjunctivitis initiated by partner Ocumension Therapeutics in China U.S.… Continue reading Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights